Exploring the effects of mavacamten through hemodynamic force analysis in patients with obstructive hypertrophic cardiomyopathy

2 September 2024 (12:15 - 12:30)

Organised by:

Video

Sign in for access options

Abstract

Slides

About the speaker

Doctor Alessandra Milazzo

Careggi University Hospital (AOUC), Florence (Italy)

3 More presentations in this session

Presentation thumbnail

Serial changes in left and right ventricular global longitudinal strain in symptomatic obstructive hypertrophic cardiomyopathy treated with mavacamten: insights from VALOR-HCM trial

Doctor M. Desai (Cleveland, US)

Abstract Slides Video

Presentation thumbnail

A comprehensive evaluation of available evidence of mavacamten in obstructive HCM: a meta-analysis of randomised controlled trials.

Doctor A. Elmorsy (Tanta, EG)

Abstract Slides Video

Presentation thumbnail

Mavacamten in a real-world hypertrophic cardiomyopathy population: how many may be eligible?

Doctor M. Lima (Lisbon, PT)

Abstract Slides Video

Access the full session

Session thumbnail

Cardiac myosin inhibitors for treatment of hypertrophic obstructive cardiomyopathy

The Event

Event poster

ESC Congress 2024

2 September 2024 12:15 CET

You may be interested in

Congress Session

Cardiac myosin inhibitors for treatment of hypertrophic obstructive cardiomyopathy

Congress Presentation

Effect of Mavacamten on left ventricular diastolic function and left atrial function in obstructive hypertrophic cardiomyopathy

Congress Presentation

Echocardiographic changes in nonobstructive hypertrophic cardiomyopathy patients treated with mavacamten: A sub-study of the ODYSSEY-HCM trial

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources